Search
EHA Blood Cancer Awareness Month Wrap-up
The first European Hematology Association (EHA) Blood Cancer Awareness Month digital campaign aimed to raise awareness of hematological malignancies and EHA’s commitment “towards a cure for all blood disorders”.
Read moreFrom Plans to Action: European Cancer Summit
From Plans to Action: European Cancer Summit (Brussels-Hybrid, November 17-18, 2021)
November 17- 18 marks the first anniversary of EHA’s membership to the European Cancer Organisation (ECO), as well as the event dates for the 2021 European Cancer Summit.
Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read moreMulti-center acute myeloid leukemia study update, December 2023
A project update from Prof Maria Teresa Voso. We successfully completed the data collection and harmonization phases, and are now in the process of data analysis.
Read moreEU projects
Creating a better world requires teamwork, partnerships, and collaboration. #bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.
Read moreHighlights from the SWG
Project groupsPan-European Transfusion Research infrAstructure (PETRA) projectThe European Blood Alliance has provided funding for a health science data project entitled: ‘Towards a Pan-European Transfusion Research infrAstructure (PETRA).
Read morePublications
The publications of the ESLHO networks can be found on the following pages:
EuroFlow publications
EuroMRD publications
EuroClonality publications
The publications from 2023 are also listed below.
EU Parliament agrees on pharmaceutical legislation stance
On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.
Read moreEHA Research Grant review and selection process
1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- »